Fasting hepatic de novo lipogenesis is not reliably assessed using circulating fatty acid markers

被引:18
|
作者
Rosqvist, Fredrik [1 ,2 ]
McNeil, Catriona A. [1 ]
Pramfalk, Camilla [1 ,3 ]
Parry, Sion A. [1 ]
Low, Wee Suan [1 ]
Cornfield, Thomas [1 ]
Fielding, Barbara A. [4 ]
Hodson, Leanne [1 ,5 ]
机构
[1] Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England
[2] Uppsala Univ, Dept Publ Hlth & Caring Sci, Clin Nutr & Metab, Uppsala, Sweden
[3] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Clin Chem, Dept Lab Med, Stockholm, Sweden
[4] Univ Surrey, Fac Hlth & Med Sci, Guildford, Surrey, England
[5] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford, England
来源
AMERICAN JOURNAL OF CLINICAL NUTRITION | 2019年 / 109卷 / 02期
基金
英国生物技术与生命科学研究理事会;
关键词
de novo lipogenesis; fatty acids; metabolism; human; triglycerides; lipogenic index; SCD; palmitoleic acid; ADIPOSE-TISSUE; VLDL-TRIGLYCERIDE; HUMAN PLASMA; LIVER; BLOOD; PATHWAY; RISK; LIPOPROTEINS; CHOLESTEROL; CONTRIBUTES;
D O I
10.1093/ajcn/nqy304
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Observational studies often infer hepatic de novo lipogenesis (DNL) by measuring circulating fatty acid (FA) markers; however, it remains to be elucidated whether these markers accurately reflect hepatic DNL. Objectives: We investigated associations between fasting hepatic DNL and proposed FA markers of DNL in subjects consuming their habitual diet. Methods: Fasting hepatic DNL was assessed using (H2O)-H-2(deuterated water) in 149 nondiabetic men and women and measuring the synthesis of very low-density lipoprotein triglyceride (VLDL-TG) palmitate. FA markers of blood lipid fractions were determined by gas chromatography. Results: Neither the lipogenic index (16: 0/18: 2n-6) nor the SCD index (16: 1n-7/16: 0) in VLDL-TG was associated with isotopically assessed DNL (r = 0.13, P = 0.1 and r = -0.08, P = 0.35, respectively). The relative abundances (mol%) of 14: 0, 16: 0, and 18: 0 in VLDL-TG were weakly (r <= 0.35) associated with DNL, whereas the abundances of 16: 1n-7, 18: 1n-7, and 18: 1n-9 were not associated. When the cohort was split by median DNL, only the abundances of 14: 0 and 18: 0 in VLDL-TG could discriminate between subjects having high (11.5%) and low(3.8%) fasting hepatic DNL. Based on a subgroup, FA markers in total plasma TG, plasma cholesteryl esters, plasma phospholipids, and red blood cell phospholipids were generally not associated with DNL. Conclusions: The usefulness of circulating FAs as markers of hepatic DNL in healthy individuals consuming their habitual diet is limited due to their inability to discriminate clearly between individuals with low and high fasting hepatic DNL.
引用
收藏
页码:260 / 268
页数:9
相关论文
共 50 条
  • [31] Circulating de novo lipogenesis fatty acids and all-cause mortality in a prospective Dutch population cohort
    Zhu, Yinjie
    Vogelpohl, Fabian A.
    Heiner-Fokkema, Rebecca
    Pranger, Ilse G.
    Minovic, Isidor
    Navis, Gerjan J.
    Bakker, Stephan J. L.
    Riphagen, Ineke J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 658 - 666
  • [32] INHIBITION OF HEPATIC DE NOVO LIPOGENESIS TO REDUCE FATTY LIVER: EFFECTS OF SREBP-1 GENE SILENCING
    Morral, N.
    Ruiz, R.
    Ahn, M.
    Surendran, S.
    Jideonwo, V.
    Gamble, A.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S494 - S495
  • [33] MODEL FOR MEASURING ABSOLUTE RATES OF HEPATIC DE-NOVO LIPOGENESIS AND REESTERIFICATION OF FREE FATTY-ACIDS
    HELLERSTEIN, MK
    NEESE, RA
    SCHWARZ, JM
    AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (05): : E814 - E820
  • [34] INHIBITION OF FATTY ACID SYNTHASE (FASN) WITH FT-4101 REDUCES HEPATIC DE NOVO LIPOGENESIS (DNL) IN HEALTHY ADULT SUBJECTS.
    Beysen, Carine
    Dole, Kiran
    Schroeder, Patricia
    Brevard, Julie
    Ribadeneira, Maria
    Sheth, Pratik
    Mishkin, Aimee
    O'Reilly, Terry E.
    HEPATOLOGY, 2019, 70 : 1273A - 1274A
  • [35] Short-Term Growth Hormone Administration Mediates Hepatic Fatty Acid Uptake and De Novo Lipogenesis Gene Expression in Obese Rats
    Likitnukul, Sutharinee
    Thammacharoen, Sumpun
    Sriwatananukulkit, Orada
    Duangtha, Chanathip
    Hemstapat, Ruedee
    Sunrat, Chotchanit
    Mangmool, Supachoke
    Pinthong, Darawan
    BIOMEDICINES, 2023, 11 (04)
  • [36] Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol
    Hodson, Leanne
    Parry, Sion A.
    Cornfield, Thomas
    Charlton, Catriona
    Low, Wee Suan
    Green, Charlotte J.
    Rosqvist, Fredrik
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2020, 125 (03) : 211 - 216
  • [37] Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice
    Cordoba-Chacon, Jose
    Majumdar, Neena
    List, Edward O.
    Diaz-Ruiz, Alberto
    Frank, Stuart J.
    Manzano, Anna
    Bartrons, Ramon
    Puchowicz, Michelle
    Kopchick, John J.
    Kineman, Rhonda D.
    DIABETES, 2015, 64 (09) : 3093 - 3103
  • [38] A New Methodology for the Reproducible Measurement of Hepatic De Novo Lipogenesis in Humans
    Beysen, Carine
    Turner, Scott
    Carvajal-Gonzalez, Santos
    Buckeridge, Clare
    Hellerstein, Marc
    Esler, William P.
    Sonnen-Berg, Gabriele E.
    DIABETES, 2014, 63 : A461 - A461
  • [39] Spot 14 gene deletion increases hepatic de novo lipogenesis
    Zhu, QH
    Mariash, A
    Margosian, MR
    Gopinath, S
    Fareed, MT
    Anderson, GW
    Mariash, CN
    ENDOCRINOLOGY, 2001, 142 (10) : 4363 - 4370
  • [40] Sex Differences in Hepatic De Novo Lipogenesis with Acute Fructose Feeding
    Low, Wee Suan
    Cornfield, Thomas
    Charlton, Catriona A.
    Tomlinson, Jeremy W.
    Hodson, Leanne
    NUTRIENTS, 2018, 10 (09)